MedPath

Alendronic acid

Generic Name
Alendronic acid
Brand Names
Adrovance, Binosto, Fosamax, Fosamax Plus D, Fosavance
Drug Type
Small Molecule
Chemical Formula
C4H13NO7P2
CAS Number
66376-36-1
Unique Ingredient Identifier
X1J18R4W8P

Overview

Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Background

Alendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone.

Indication

Alendronic acid is indicated for the treatment and prevention of osteoporosis in men and postmenopausal women, treatment of glucocorticoid-induced osteoporosis, and Paget's disease of bone. However, alendronic acid is not indicated for use in pediatric populations or patients with a creatinine clearance <35mL/min.

Associated Conditions

  • Osteogenesis Imperfecta (OI)
  • Osteoporosis
  • Osteoporosis caused by Glucocorticoid Treatment
  • Paget’s Disease

FDA Approved Products

Binosto
Manufacturer:ASCEND Therapeutics
Route:ORAL
Strength:70 mg in 1 1
Approved: 2023/12/20
NDC:17139-400

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath